Weiss Ratings Reiterates "Sell (E+)" Rating for Greenwich LifeSciences (NASDAQ:GLSI)

Key Points

• Weiss Ratings has reaffirmed its "Sell (E+)" rating for Greenwich LifeSciences (NASDAQ:GLSI) in a recent report to clients and investors.
• Noble Financial has initiated coverage on the company, giving it an "outperform" rating with a price target of $45.00.
• Greenwich LifeSciences shares are currently trading at $10.49, with a 12-month low of $8.06 and a high of $15.47, reflecting a volatile price trend.

Greenwich LifeSciences (NASDAQ:GLSI - Get Free Report)'s stock had its "sell (e+)" rating reaffirmed by equities research analysts at Weiss Ratings in a research report issued to clients and investors on Tuesday,Weiss Ratings reports.

Separately, Noble Financial started coverage on Greenwich LifeSciences in a research note on Wednesday, August 20th. They issued an "outperform" rating and a $45.00 price target on the stock. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $42.00.

Greenwich LifeSciences Stock Up 1.8%

Shares of NASDAQ GLSI traded up $0.19 on Tuesday, hitting $10.49. The company had a trading volume of 46,937 shares, compared to its average volume of 60,493. Greenwich LifeSciences has a 12-month low of $8.06 and a 12-month high of $15.47. The business has a 50 day moving average of $11.37 and a two-hundred day moving average of $10.40. The firm has a market capitalization of $142.98 million, a P/E ratio of -7.71 and a beta of 1.62.

Greenwich LifeSciences (NASDAQ:GLSI - Get Free Report) last issued its earnings results on Thursday, August 14th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.06). On average, sell-side analysts anticipate that Greenwich LifeSciences will post -0.8 earnings per share for the current year.

Institutional Trading of Greenwich LifeSciences

Several institutional investors and hedge funds have recently bought and sold shares of the company. Marshall Wace LLP acquired a new stake in Greenwich LifeSciences during the second quarter valued at approximately $509,000. Police & Firemen s Retirement System of New Jersey acquired a new stake in Greenwich LifeSciences during the second quarter valued at approximately $25,000. Geode Capital Management LLC raised its stake in Greenwich LifeSciences by 1.4% during the second quarter. Geode Capital Management LLC now owns 138,982 shares of the company's stock valued at $1,261,000 after buying an additional 1,972 shares in the last quarter. Rhumbline Advisers raised its stake in Greenwich LifeSciences by 48.7% during the first quarter. Rhumbline Advisers now owns 9,673 shares of the company's stock valued at $92,000 after buying an additional 3,168 shares in the last quarter. Finally, Strs Ohio acquired a new stake in Greenwich LifeSciences during the first quarter valued at approximately $177,000. Institutional investors and hedge funds own 4.16% of the company's stock.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.